Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Response Genetics's Days Sales Outstanding or its related term are showing as below:
RGDXQ's Days Sales Outstanding is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 67.59 * Ranked among companies with meaningful Days Sales Outstanding only.
Response Genetics's Days Sales Outstanding
increased
from Mar. 2014 (137.69) to Mar. 2015 (166.94).
Response Genetics (OTCPK:RGDXQ) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Response Genetics Days Sales Outstanding Related Terms
Response Genetics Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Response Genetics's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RGDXQ vs PSID, GBSN, ETAH: Days Sales Outstanding Comparison
For the Diagnostics & Research subindustry, Response Genetics's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Response Genetics Days Sales Outstanding vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Response Genetics's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Response Genetics's Days Sales Outstanding falls into.
Response Genetics Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Days Sales Outstanding of 166.94 mean?
Response Genetics (RGDXQ) has a Days Sales Outstanding of 166.94 as of Mar. 2015. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Response Genetics and its competitors.
Is Response Genetics' Days Sales Outstanding too high?
Response Genetics' current Days Sales Outstanding is 166.94. The Medical Diagnostics & Research industry median Days Sales Outstanding is 67.59. Response Genetics' value of 166.94 is 147% above this industry median.
How does Response Genetics' Days Sales Outstanding compare to PSID and GBSN?
Response Genetics' Days Sales Outstanding of 166.94 can be compared against companies in the Medical Diagnostics & Research industry. The industry median Days Sales Outstanding is 67.59. Response Genetics' value of 166.94 is 147% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Medical Diagnostics & Research company?
The median Days Sales Outstanding among Medical Diagnostics & Research companies is 67.59, based on 201 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Response Genetics's current Days Sales Outstanding of 166.94 is 147% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Response Genetics and its competitors. For the Medical Diagnostics & Research industry, the median Days Sales Outstanding is 67.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Response Genetics's current Days Sales Outstanding is 166.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Response Genetics stock overvalued right now?
Response Genetics (RGDXQ) has a current Days Sales Outstanding of 166.94. The current Days Sales Outstanding is 166.94 and 147% above the Medical Diagnostics & Research industry median of 67.59. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Response Genetics (RGDXQ), the current Days Sales Outstanding is 166.94 as of Mar. 2015. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Response Genetics Inc develops and sells diagnostic tests. It provides molecular- and biomarker-based tests and services which enables physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor and inform cancer treatment. The group generates revenue from providing Biopharma Services, Clinical Services, and Discovery Services, of which majority of the revenue is derived from providing Biopharma Services. Biopharma services provide companies with customized solutions for patient stratification and treatment selection through molecular- and biomarker-based testing services, customized assay development and trial design consultation. The firm operates in the US and internationally and generates prime revenue from the US.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RGDXQ has been successfully added to your 
